DEF6(differentially exprehomolog) exacerbates pathological cardiac hypertrophy via RAC1

DEF6(differentially exprehomolog) exacerbates pathological cardiac hypertrophy via RAC1

Abstract Pathological cardiac hypertrophy involves multiple regulators and several signal transduction pathways. Currently, the mechanisms of it are not well understood. Differentially expressed in FDCP 6 homolog (DEF6) was reported to participate in immunity, bone remodeling, and cancers. The effec...

Full description

Bibliographic Details
Main Authors:	Yan Sun, Changlu Xu, Zhongxiu Jiang, Xi Jiang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-07-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-023-05948-0

Similar Items

Therapeutic potentials of modulating autophagy in pathological cardiac hypertrophy
by: Shenggan Shi, et al.
Published: (2022-12-01)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
by: Ke-Qiong Deng, et al.
Published: (2016-06-01)

CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signaling pathway
by: Yue Li, et al.
Published: (2023-11-01)

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy
by: Dan Yang, et al.
Published: (2022-01-01)

Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
by: Ke-Qiong Deng, et al.
Published: (2023-05-01)

SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy
by: Xin Shi, et al.
Published: (2024-03-01)

Raising the level for $\def \xmlpi #1{}\def \mathsfbi #1{\boldsymbol {\mathsf {#1}}}\let \le =\leqslant \let \leq =\leqslant \let \ge =\geqslant \let \geq =\geqslant \def \Pr {\mathit {Pr}}\def \Fr {\mathit {Fr}}\def \Rey {\mathit {Re}}\text {GL}_{{n}}$
by: JACK A. THORNE
Published: (2014-06-01)

Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy
by: Joana Silva, et al.
Published: (2022-05-01)

ANGPTL8 is a negative regulator in pathological cardiac hypertrophy
by: Lin Hu, et al.
Published: (2022-07-01)

DEFS—Data Exchange with Free Sample Protocol
by: Rafael Genés-Durán, et al.
Published: (2021-06-01)

Defining scalable high performance programming with DEF
by: Leiserson, William Mitchell.
Published: (2020)

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy
by: Changlin Zhen, et al.
Published: (2023-03-01)

Def6 regulates endogenous type-I interferon responses in osteoblasts and suppresses osteogenesis
by: Zhonghao Deng, et al.
Published: (2020-12-01)

Divergent and Overlapping Roles for Selected Phytochemicals in the Regulation of Pathological Cardiac Hypertrophy
by: Levi Evans, et al.
Published: (2021-02-01)

Multiple short‐chain dehydrogenases/reductases are regulated in pathological cardiac hypertrophy
by: Elise Roussel, et al.
Published: (2018-10-01)

Elevated dietary sodium intake exacerbates myocardial hypertrophy associated with cardiac-specific overproduction of angiotensin II
by: Enzo R Porrello, et al.
Published: (2004-12-01)

DEF6 has potential to be a biomarker for cancer prognosis: A pan-cancer analysis
by: Ziming Yuan, et al.
Published: (2023-01-01)

Protections of transcription factor BACH2 and natural product myricetin against pathological cardiac hypertrophy and dysfunction
by: Xueli Jiang, et al.
Published: (2022-08-01)

E3 ubiquitin ligase RNF5 attenuates pathological cardiac hypertrophy through STING
by: Lu-Lu Yang, et al.
Published: (2022-10-01)

Influence of the Ambient Relative Humidity on the Very-Long-Term DEF
by: Thierry Houndonougbo, et al.
Published: (2023-11-01)

Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance
by: Petersen, SE, et al.
Published: (2004)

Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance.
by: Petersen, SE, et al.
Published: (2005)

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
by: Yan Chen, et al.
Published: (2022-08-01)

Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes
by: Zhirong Lin, et al.
Published: (2022-05-01)

Derangement of cardiac energy metabolism is acutely exacerbated during exercise in hypertrophic cardiomyopathy, independent of hypertrophy or late gadolinium burden
by: Dass, S, et al.
Published: (2012)

Derangement of cardiac energy metabolism is acutely exacerbated during exercise in hypertrophic cardiomyopathy, independent of hypertrophy or late gadolinium burden
by: Dass Sairia, et al.
Published: (2012-02-01)

DEF of high-performance concrete with rapid, non-standard heat-treatment
by: Jan Stindt, et al.
Published: (2023-12-01)

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy
by: Farhad Bazgir, et al.
Published: (2023-07-01)

Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome
by: Levi Evans, et al.
Published: (2023-08-01)

Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice
by: Gen Chen, et al.
Published: (2023-03-01)

FGF13 Is a Novel Regulator of NF-κB and Potentiates Pathological Cardiac Hypertrophy
by: Jia Sun, et al.
Published: (2023-06-01)

Improved Prostate Biparameter Magnetic Resonance Image Segmentation Based on Def-UNet
by: Xunan Huang, et al.
Published: (2023-01-01)

Evaluasi Sistem Informasi Akuntansi Pendapatan dan Persediaan Pada PT. DEF
by: Kriswanto Kriswanto
Published: (2012-11-01)

SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
by: Qiaofeng Qian, et al.
Published: (2023-04-01)

Evaluation of cardiac hypertrophy in the setting of sudden cardiac death
by: Kristopher S. Cunningham, et al.
Published: (2019-07-01)

The Prevention Role of Theaflavin-3,3′-digallate in Angiotensin II Induced Pathological Cardiac Hypertrophy via CaN-NFAT Signal Pathway
by: Hui Zhou, et al.
Published: (2022-03-01)

Tamponade caused by cardiac lipomatous hypertrophy.
by: Myerson, S, et al.
Published: (2004)

Mitochondrial Dysfunction in Arrhythmia and Cardiac Hypertrophy
by: Xiaomei Wang, et al.
Published: (2023-12-01)

Actin-Binding Proteins in Cardiac Hypertrophy
by: Congbin Pan, et al.
Published: (2022-11-01)

Ferroptosis in cardiac hypertrophy and heart failure
by: Kuo Zhang, et al.
Published: (2023-12-01)